Table 1.
SARS-CoV-2 mRNA vaccines in lipid nanoparticle formulations.
| Company /Sponsor |
mRNA Type | Immunogens | mRNA Dose (μg) | Clinic Data |
Preclinical Data |
|---|---|---|---|---|---|
| Moderna | Base-modified mRNA | mRNA-1273: prefusion stabilized Spike-TM | 100 | FDA approved [9] | [30,31] |
| Pfizer/BioNTech | Base-modified mRNA | BNT162b2: prefusion stabilized Spike-TM | 30 | FDA approved [10] | [32] |
| Pfizer/BioNTech | Base-modified mRNA | BNT162b1: receptor binding domain | 30 | phase 2 [114] | |
| CureVac | Unmodified mRNA | CVnCoV: prefusion stabilized Spike-TM | 12 | phase 2b/3 [116] | [105] |
| Arcturus | Self-amplifying mRNA | ARCT-021: full length Spike | 1–10 | phase ½ | [117] |
| Imperial College | Self-amplifying mRNA | full length Spike | 1–10 | [118] | |
| TranslateBio /Sanofi |
Unmodified mRNA | prefusion stabilized Spike-TM (MRT55500) | 7.5 | [109] |
Spike-TM: full-length spike with transmembrane domain.